Ifinatamab Deruxtecan Accelerated Filing Withdrawn

Company Daiichi Sankyo; Merck Event Type Accelerated Approval Application Withdrawn Modality Antibody-Drug Conjugate Asset Ifinatamab Deruxtecan Target B7-H3 Disease Area Extensive-Stage Small-Cell Lung Cancer Summary Daiichi Sankyo and Merck voluntarily withdrew the U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer…